ZLAB Projected Dividend Yield

ADR/Zai Lab Ltd ( NASDAQ : ZLAB )

Zai Lab is a holding company. Through its subsidiaries, Co. is a commercial-stage biopharmaceutical company focusing on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of unmet medical need in the China and global markets, including in the fields of oncology, infectious and autoimmune diseases. Co.'s products are: Niraparib, a selective oral, small molecule PARP 1/2 inhibitor with the potential to be a drug for treatment across multiple solid tumor types in China; and Optune, a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing affected cancer cells to die.

20 YEAR PERFORMANCE RESULTS